ReviewThe American journal of gastroenterology2021
Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.
Review in The American journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 49 citations in OpenAlex.
- The efficacy and safety of hyoscyamine, dicyclomine, and desipramine in the treatment of irritable pouch syndrome-a retrospective cohort study.Crohn's & colitis 360 · 2026Article
- Spinacetin, an Anti-Inflammatory Natural Compound with Multiple Pharmacological Properties.Current issues in molecular biology · 2026Review
- Revisiting Abdominal Pain in IBS: From Pathophysiology to Targeted Management with Alverine Citrate/Simeticone.Journal of clinical medicine · 2026Review
- Antispasmodic activity of a series of cyclic imides (phthalimides) derivatives.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Review
- Modeling Pain Dynamics and Opioid Response in Oncology Inpatients: A Retrospective Study with Application to AI-Guided Analgesic Strategies in Colorectal Cancer.Medicina (Kaunas, Lithuania) · 2025Observational
- The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population-Based Study.Alimentary pharmacology & therapeutics · 2025Article
- Chronic Abdominal Discomfort Syndrome (CADS): A Narrative Review of Treatment Strategies.Journal of pain research · 2025Article
- Borneol's Pre-Clinical Analgesic Efficacy: Mediated by Receptor and Immune Mechanisms.Journal of pain research · 2025Review
- Chronic Abdominal Pain in Patients with Inflammatory Bowel Disease in Remission: A Continuing Challenge for Clinicians.Digestive diseases and sciences · 2024Review
- Spasmolytic Activity and Anti-Inflammatory Effect of Novel Mebeverine Derivatives.Biomedicines · 2024Article
- Novel Anthranilic Acid Hybrids-An Alternative Weapon against Inflammatory Diseases.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Bioactivity of the GenusPharmaceuticals (Basel, Switzerland) · 2023Review
- Abdominal Pain in Inflammatory Bowel Disease: An Evidence-Based, Multidisciplinary Review.Crohn's & colitis 360 · 2023Article
- Randomized clinical trial: the effects of pregabalin for centrally mediated abdominal pain syndrome.Therapeutic advances in gastroenterology · 2023Article
- Current and Future Strategies for the Diagnosis and Treatment of the Alpha-Gal Syndrome (AGS).Journal of asthma and allergy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic abdominal pain is a common gastrointestinal (GI) symptom that characterizes many functional GI disorders/disorders of gut-brain interaction, including irritable bowel syndrome, functional dyspepsia, and centrally mediated abdominal pain syndrome. The symptoms of abdominal pain in these highly prevalent disorders are often treated with antispasmodic agents. Antispasmodic treatment includes a broad range of therapeutic classes with different mechanisms of action, including anticholinergic/antimuscarinic agents (inhibition of GI smooth muscle contraction), calcium channel inhibitors (inhibition of calcium transport into GI smooth muscle), and direct smooth muscle relaxants (inhibition of sodium and calcium transport). The aim of this review article was to examine the efficacy and safety of antispasmodics available in North America (e.g., alverine, dicyclomine, hyoscine, hyoscyamine, mebeverine, otilonium, pinaverium, and trimebutine) for the treatment of chronic abdominal pain in patients with common disorders of gut-brain interaction. For the agents examined, comparisons of studies are limited by inconsistencies in treatment dosing and duration, patient profiles, and diagnostic criteria employed. Furthermore, variability in study end points limits comparisons. Risk of selection, performance, detection, attrition, and reporting bias also differed among studies, and in many cases, risks were considered "unclear." The antispasmodics evaluated in this review, which differ in geographic availability, were found to vary dramatically in efficacy and safety. Given these caveats, each agent should be considered on an individual basis, rather than prescribed based on information across the broad class of agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.